Vita 34 International AG: Further collaboration agreed with a compulsory health insurance fund, BKK Ost-Hessen supports the storage of umbilical cord blood at VITA 34

Vita 34 International AG / Alliance

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
The issuer / publisher is solely responsible for the content of this announcement.

Leipzig, 1 September 2007 – VITA 34 International AG (ISIN DE000A0BL849),
the parent company of the leading private umbilical cord blood bank in the
German-speaking countries, Vita 34, has gained BKK Ost-Hessen as another
compulsory health insurance fund cooperation partner. This provides VITA 34
with even more expert support for the private storage of umbilical cord

With immediate effect, BKK Ost-Hessen is promoting the preparation and
storage of umbilical cord blood at VITA 34. As a result, people insured by
BKK Ost-Hessen are being offered attractive discount schemes for storing
umbilical cord blood. On concluding a standard agreement with VITA 34,
prospective parents receive a one-off discount of EUR 250. In addition,
price models have been developed to match individual customer requirements.

VITA 34 gained the first compulsory health insurance fund, BKK FAHR, for
promotion of private storage of umbilical cord blood in April 2007. The new
collaboration which has now been agreed with BKK Ost-Hessen is further
proof of the considerable signalling effect produced by such collaboration.
VITA 34 is expecting other private and compulsory health insurance funds to
follow this example. VITA 34 has already been involved in cooperation with
a major private health insurance fund, Debeka, for quite some time. The new
partners are demonstrating the success of the marketing and sales offensive
which has already been initiated.

BKK Ost-Hessen provides insurance for some 21,000 people. VITA 34 is also
looking for further cooperation agreements with private as well as
compulsory health insurance providers. The company is at the advanced stage
of negotiation in this respect.

About VITA 34:

With a market share of around 66%, VITA 34 is the leading private umbilical
cord blood bank in the German-speaking countries. There are absolutely no
ethical objections to stem cell transplants from umbilical cord blood. Such
transplants are suitable for curing diseases as well as for use in
regenerative medicine. Due to the rapid advancement in research and
medicine, it is not possible at present to foresee the complete range of
applications for umbilical cord blood stem cells. VITA 34 focuses on the
production of autologous stem cell preparations, i.e. those produced
naturally by the body. Compared with other countries, there is still
considerable room for development on the German market with regard to
umbilical blood storage by parents.

Press/Investor Relation:
Axel Mühlhaus
Dr Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550552
Fax: +49 (069) 90550577

DGAP 01.08.2007 
Language:     English
Issuer:       Vita 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service